FGFR1 and adenocarcinoma: In NSCLC patients, FGFR1 amplifications regulates cell proliferation through activation of the MAPK and PI3K/AKT pathways in about 20% of squamous cell carcinomas but they are rarely detected in adenocarcinomas [4].